Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Notes Payables (2020 - 2025)

Catheter Precision (VTAK) has disclosed Notes Payables for 5 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • Quarterly Notes Payables rose 422.09% to $1.3 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Sep 2025, up 422.09% year-over-year, with the annual reading at $1.6 million for FY2024, 769.57% up from the prior year.
  • Notes Payables for Q3 2025 was $1.3 million at Catheter Precision, roughly flat from $1.3 million in the prior quarter.
  • The five-year high for Notes Payables was $14.2 million in Q2 2023, with the low at $7592.0 in Q1 2023.
  • Average Notes Payables over 4 years is $3.4 million, with a median of $987000.0 recorded in 2021.
  • Peak annual rise in Notes Payables hit 769.57% in 2024, while the deepest fall reached 98.24% in 2024.
  • Over 4 years, Notes Payables stood at $674000.0 in 2021, then tumbled by 72.7% to $184000.0 in 2023, then surged by 769.57% to $1.6 million in 2024, then dropped by 18.75% to $1.3 million in 2025.
  • According to Business Quant data, Notes Payables over the past three periods came in at $1.3 million, $1.3 million, and $102000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.